University of Groningen
The aberrant transcriptional program of myeloid malignancies with poor prognosis
Gerritsen, Myléne
DOI:
10.33612/diss.113503008
IMPORTANT NOTE: You are advised to consult the publisher's version (publisher's PDF) if you wish to cite from
it. Please check the document version below.
Document Version
Publisher's PDF, also known as Version of record
Publication date:
2020
Link to publication in University of Groningen/UMCG research database
Citation for published version (APA):
Gerritsen, M. (2020). The aberrant transcriptional program of myeloid malignancies with poor prognosis:
the effects of RUNX1 and TP53 mutations in AML. Rijksuniversiteit Groningen.
https://doi.org/10.33612/diss.113503008
Copyright
Other than for strictly personal use, it is not permitted to download or to forward/distribute the text or part of it without the consent of the author(s) and/or copyright holder(s), unless the work is under an open content license (like Creative Commons).
Take-down policy
If you believe that this document breaches copyright please contact us providing details, and we will remove access to the work immediately and investigate your claim.
Downloaded from the University of Groningen/UMCG research database (Pure): http://www.rug.nl/research/portal. For technical reasons the number of authors shown on this cover page is limited to 10 maximum.
The aberrant transcriptional program of
myeloid malignancies with poor prognosis
The effects of RUNX1 and TP53 mutations in AML
COLOPHON
Cover design: James Jardine | www.jamesjardine.nl Layout: James Jardine | www.jamesjardine.nl Print: Ridderprint | www.ridderprint.nl ISBN: 978-94-6375-764-5 (print)
978-94-6375-765-2 (digital)
Copyright © 2019 by Myléne Gerritsen. All rights reserved. Any unauthorized reprint or use of this material is prohibited. No part of this thesis may be reproduced, stored or transmitted in any form or by any means, without written permission of the author or, when appropriate, of the publishers
The aberrant transcriptional program of myeloid
malignancies with poor prognosis
The effects of RUNX1 and TP53 mutations in AML
Proefschrift
ter verkrijging van de graad van doctor aan de Rijksuniversiteit Groningen
op gezag van de
rector magnificus prof. dr. C. Wijmenga en volgens besluit van het College voor Promoties.
De openbare verdediging zal plaatsvinden op woensdag 4 maart 2020 om 16.15 uur
door
Myléne Gerritsen
geboren op 16 oktober 1988Promotores
Prof. dr. E. Vellenga Prof. dr. J.J. SchuringaCo-Promotor
Dr. J.H.A MartensBeoordelingscommissie
Prof. dr. H.G. Stunnenberg Prof. dr. G. de Haan Prof. dr. M.A.T.M. van VugtTABLE OF CONTENTS
Chapter 1 General introduction and scope of the thesis 7
Chapter 2 RUNX1 mutations enhance self-renewal and block granulocytic
differentiation in human in vitro models and primary AMLs.
Blood Advances 2019; 3: 320
27
Chapter 3 TCF4 is an important target for mutant RUNX1 and its expression
predicts clinical outcome in acute myeloid leukemia
Parts are published in Haematologica
63
Chapter 4 Mutant p53 increases stem-cell frequency and has reduced binding to classic p53 binding sites in primary AMLs and cell lines.
Submitted
85
Chapter 5 Ring sideroblasts in AML are clonally derived, associated with adverse risk characteristics and have a distinct gene expression pattern
Blood Advances 2019; 3: 3111
103
Chapter 6 Summary, General Conclusion and Discussion 155
Appendices Nederlandse samenvatting voor “niet ingewijden”
Dankwoord List of Publications
175 179 183
